We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+18.58%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$733M
AUM Growth
-$135M
Cap. Flow
-$230M
Cap. Flow %
-31.36%
Top 10 Hldgs %
42.15%
Holding
113
New
16
Increased
22
Reduced
29
Closed
27

Top Buys

Rank Stock Value
1
ORKA
Oruka Therapeutics
ORKA
+$12M
2
NUVL
Nuvalent
NUVL
+$11.4M
3
ALKS icon
Alkermes
ALKS
+$9.33M
4
ARWR icon
Arrowhead Research
ARWR
+$6.71M
5
VRDN icon
Viridian Therapeutics
VRDN
+$6.13M

Top Sells

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$20.4M
2
ONC
BeOne Medicines Ltd
ONC
+$13.5M
3
CLDX icon
Celldex Therapeutics
CLDX
+$13.4M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$8.54M
5
APGE icon
Apogee Therapeutics
APGE
+$8.25M

Sector Composition

Rank Sector Weight
1 Healthcare 81.54%
2 Financials 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONC
26
BeOne Medicines Ltd
ONC
$32.2B
$7.86M 1.07%
35,000
-75,000
-68% -$13.5M
NAMS icon
27
NewAmsterdam Pharma
NAMS
$3.47B
$7.84M 1.07%
472,390
+49,235
+12% +$852K
BBIO icon
28
BridgeBio Pharma
BBIO
$15.8B
$7.64M 1.04%
300,000
+200,000
+200% +$5.25M
CLYM
29
Climb Bio
CLYM
$700M
$7.63M 1.04%
1,500,000
-170,661
-10% -$1.21M
AXSM icon
30
Axsome Therapeutics
AXSM
$11.4B
$7.19M 0.98%
80,000
– –
ERAS icon
31
Erasca
ERAS
$6.53B
$6.82M 0.93%
2,499,431
– –
GERN icon
32
Geron
GERN
$924M
$6.81M 0.93%
1,500,000
– –
ANAB icon
33
PUT
AnaptysBio
ANAB
$1.49B
$6.7M 0.91%
+200,000
New +$6.83M
CATX icon
34
Perspective Therapeutics
CATX
$333M
$6.67M 0.91%
500,000
-50,000
-9% -$665K
IMVT icon
35
Immunovant
IMVT
$8.2B
$6.41M 0.88%
225,000
-121,088
-35% -$3.57M
ARWR icon
36
Arrowhead Research
ARWR
$10.1B
$6.3M 0.86%
325,000
+275,000
+550% +$6.71M
SPRY icon
37
CALL
ARS Pharmaceuticals
SPRY
$640M
$5.8M 0.79%
+400,000
New +$4.76M
PCVX icon
38
Vaxcyte
PCVX
$8.01B
$5.71M 0.78%
50,000
-10,000
-17% -$901K
ARVN icon
39
Arvinas
ARVN
$517M
$5.54M 0.76%
+225,000
New +$5.88M
TERN
40
DELISTED
Terns Pharmaceuticals
TERN
$5M 0.68%
+600,000
New +$4.94M
SWTX
41
DELISTED
SpringWorks Therapeutics
SWTX
$4.73M 0.64%
147,500
+77,501
+111% +$2.9M
CGEM icon
42
Cullinan Oncology
CGEM
$1.08B
$4.42M 0.6%
263,817
– –
CLDX icon
43
Celldex Therapeutics
CLDX
$2.78B
$4.25M 0.58%
125,000
-350,400
-74% -$13.4M
MLYS icon
44
Mineralys Therapeutics
MLYS
$2.35B
$4.24M 0.58%
350,000
+22,041
+7% +$267K
NVAX icon
45
CALL
Novavax
NVAX
$1.3B
$3.79M 0.52%
+300,000
New +$3.87M
INSM icon
46
Insmed
INSM
$23.2B
$3.65M 0.5%
50,000
-75,000
-60% -$5.53M
PCSC
47
Perceptive Capital Solutions
PCSC
$123M
$3.51M 0.48%
350,000
– –
GALT icon
48
PUT
Galectin Therapeutics
GALT
$263M
$3.33M 0.45%
+1,211,400
New +$2.97M
NXTC icon
49
NextCure
NXTC
$22M
$3.15M 0.43%
191,883
+51,220
+36% +$943K
SMMT icon
50
CALL
Summit Therapeutics
SMMT
$10.5B
$3.07M 0.42%
+140,000
New +$1.96M
1
2
3 4 5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Affinity Asset Advisors held 113 positions worth $733M, down 16% from $868M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Affinity Asset Advisors withdrew a net $230M in Q3 2024, closing 27 positions and reducing 29 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $20.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 65% a quarter earlier, followed by Financials.

Against the trend, Affinity Asset Advisors opened a new position in Arvinas worth $5.54M.

  • Affinity Asset Advisors's largest Q3 2024 buy was Arvinas: 225,000 shares worth $5.54M.
  • Affinity Asset Advisors added most to Oruka Therapeutics in Q3 2024, an estimated $12M increase.
  • Affinity Asset Advisors's biggest Q3 2024 reduction was BeOne Medicines Ltd, cutting an estimated $13.5M.
  • Affinity Asset Advisors fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $20.4M.
  • Affinity Asset Advisors's ten largest holdings make up 42% of its $733M portfolio in Q3 2024.
  • Affinity Asset Advisors opened 16 new positions and closed 27 in Q3 2024.
  • Affinity Asset Advisors's portfolio value fell 16% quarter-over-quarter to $733M.

Based on Affinity Asset Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.